ImmusanT, Inc.
One Broadway
14th Floor
Cambridge
Massachusetts
02142
United States
Tel: 617-401-2154
Website: http://www.immusant.com/
34 articles about ImmusanT, Inc.
-
BioSpace Movers and Shakers: Jan. 4
1/4/2019
Biopharma companies begin 2019 with a flurry of hiring to fill executive leadership spots, including Dermavant, UroGen, Melinta, Translate Bio, and more. -
ImmusanT Announces First Patient Dosed in Phase 2 Trial of Therapeutic Vaccine for Celiac Disease
9/27/2018
ImmusanT, Inc., a clinical stage company that is leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to translate and deliver first-in-class peptide-based immune therapies to patients living with autoimmune diseases, today announced that the first patient has been dosed in its Phase 2 RESET CeD trial for the treatment of celiac disease.
-
There have been a number of leadership changes in the life sciences industries over the past week. BioSpace compiled a roundup of the changing landscape of the c-suite and boards of directors across the industry.
-
ImmusanT CEO Leslie Williams to Discuss Immunology of Celiac Disease at 2018 BIO International Convention
5/24/2018
ImmusanT, Inc. today announced that Chief Executive Officer, Leslie Williams will participate on a panel and provide a company presentation at the 2018 BIO International Convention, occurring June 4-7, 2018 in Boston, MA.
-
ImmusanT Expands Management Team to Strengthen Financial Operations and Accelerate Clinical Development
5/21/2018
-- Kristin M. Neff joins as VP, Clinical Operations and Project Management – -- Joyce A. Pinkham joins as VP, Program Management – -- Jonathan Yeadon joins as Director, Finance –
-
ImmusanT Welcomes Ken Truitt, M.D. as Chief Medical Officer
5/15/2018
ImmusanT is a clinical stage company that is leveraging its Epitope-Specific Immuno-Therapy platform to translate and deliver first-in-class peptide-based immune therapies to patients living with autoimmune diseases
-
ImmusanT Provides Year-End Update and Outlines Goals for 2018
1/4/2018
ImmusanT today provided an update on accomplishments from 2017 and outlined goals for 2018.
-
ImmusanT Data Shows Up-Dosing Substantially Increases Nexvax2 Dose Levels That Are Safe and Tolerable, Further Supports Phase II Studies
11/28/2017
This study demonstrates that gradually increasing the dose from a low, well-tolerated starting dose enables Nexvax2 to be safe and tolerable without dose-limiting adverse events at a level of 900 μg,.
-
ImmusanT Raises $40M, Adds Dr. Gillis and Former Celgene Head of R&D Daniel to Board
11/14/2017
The proceeds will fund a randomized Phase II clinical trial of escalating doses of Nexvax2 in celiac patients who possess the human leukocyte antigen-DQ2.5 immune recognition gene.
-
Cambridge's ImmusanT Nabs $40M
11/14/2017
The cash will fund a randomized Phase II clinical trial of escalating doses of Nexvax2 in celiac patients who possess the human leukocyte antigen-DQ2.5 (HLA-DQ2.5) immune recognition gene. -
ImmusanT, Inc. To Present New Nexvax2 Dosing Data At United European Gastroenterology (UEG) Week
10/12/2017
-
ImmusanT, Inc. To Present And Speak At BIO Investor Forum
10/11/2017
-
ImmusanT, Inc. Presents Data From Multiple Studies Supporting Continued Development Of Nexvax2
9/11/2017
-
International Society For The Study Of Celiac Disease Release: Leading Immunologists Gather In New Delhi To Confront Celiac Disease
9/1/2017
-
ImmusanT, Inc. Announces Publication Of Positive Data From Phase I Trials Of Nexvax2 In Celiac Disease Patients
5/12/2017
-
ImmusanT, Inc. Reports Data On Novel Celiac Disease Diagnostic Approach
5/8/2017
-
ImmusanT, Inc. Announces Completion Of Phase Ib Clinical Trial Of Nexvax2 For The Treatment Of Celiac Disease
2/22/2017
-
ImmusanT, Inc. Reports Nexvax2 Phase 1 Data In Patients With Celiac Disease
5/25/2016
-
ImmusanT, Inc. Release: Journal Gastroenterology Publishes Research Indicating Nearly Identical Response To Gluten In Most Children And Adults With Celiac Disease
9/2/2015
-
ImmusanT, Inc. Release: Journal Gastroenterology Publishes Research Indicating Nearly Identical Response To Gluten In Most Children And Adults With Celiac Disease
9/2/2015